This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can
kill target cells through similar cytotoxic mechanisms. With the remarkable success of …

Natural killer (NK) cells have crucial roles in the innate immunosurveillance of cancer and
viral infections. They are 'first responders' that can spontaneously recognize abnormal cells …

Immune 'checkpoint'inhibitors can increase the activity of tumor-resident cytotoxic
lymphocytes and have revolutionized cancer treatment. Current therapies block inhibitory …

Chimeric antigen receptors (CARs) are fusion proteins with an extracellular antigen
recognition domain and numerous intracellular signaling domains that have been …

The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products
in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However …

In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach for combating cancers, demonstrating remarkable …

The development of chimeric antigen receptor (CAR) T cell therapy has introduced a new
and effective strategy to guide and promote the immune response against tumors in the …

Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have
emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy …

Gene-engineered immune cell therapies have partially transformed cancer treatment, as
exemplified by the use of chimeric antigen receptor (CAR)-T cells in certain hematologic …